Invesaro

Stocks Health care SRZN

NASDAQ · Health care

Surrozen, Inc. (SRZN)

Surrozen, Inc. brought in $11.5M of revenue over the twelve months to June 30, 2026, down 8.8% from a year earlier. It posted a net loss of $332.1M. In fiscal 2025 capital spending exceeded operating cash flow by $30.4M. At June 30, 2026 it held $102M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price
$29.54
-12.29% on the day · September 25, 2026
52-week range $11.39 to $37.83
Market cap
$347.2M
Revenue (last 12 months)
$11.5M
-8.8% year on year
Net margin
-2,885.3%

What Surrozen, Inc. does

Surrozen, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SRZN.

Revenue and profit by year

Revenue
FY21: $0 $0 FY21FY22: $12.5M $12.5M FY22FY23: $0 $0 FY23FY24: $10.7M $10.7M FY24FY25: $3.5M $3.5M FY25
Net income
FY20: -$32.7M -$32.7M FY20FY21: -$54.6M -$54.6M FY21FY22: -$36M -$36M FY22FY23: -$43M -$43M FY23FY24: -$63.6M -$63.6M FY24FY25: -$242M -$242M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$3.5M-$42.1M-$242M-$32.37-$30.4M
2024$10.7M-$25.5M-$63.6M-$21.67-$17.7M
2023$0-$45.8M-$43M-$21.33-$40.8M
2022$12.5M-$44.3M-$36M-$15.56-$44.9M
2021$0-$54.4M-$54.6M-$33.07-$50.1M
2020n/a-$32.8M-$32.7Mn/a-$30M
Next report expected around November 6, 2026.

Estimated from its filing rhythm: about 92 days after its last report of August 6, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where SRZN ranks in Health care

Revenue$3.5M
#469 of 523 in Health care · Bottom 10%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Surrozen, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
  2. August 14, 2026
  3. August 14, 2026
  4. August 11, 2026
  5. August 7, 2026
  6. August 6, 2026
    Quarterly report 10-Q · period to June 30, 2026
  7. August 6, 2026
  8. July 24, 2026
  9. May 18, 2026
  10. May 15, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 24, 2026. Insider transactions on SEC

Insider trades

What the people running Surrozen, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about SRZN

What does Surrozen, Inc. do?

Surrozen, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SRZN.

Is Surrozen, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $332.1M on revenue of $11.5M.

How much revenue does Surrozen, Inc. make?

Over the twelve months to June 30, 2026 Surrozen, Inc. reported revenue of $11.5M. That is 8.8% less than a year earlier.

When did Surrozen, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.

Similar companies

Compare SRZN with

Compare SRZN with any company

Follow SRZN

Get an email when Surrozen, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SRZN: get an email when it files

Where the numbers come from

Financial figures are the values Surrozen, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.